Experience
ProfoundBio Announces $1.8 Billion Acquisition by Genmab
April 3, 2024
Cooley advised ProfoundBio, a clinical-stage biotechnology company developing novel antibody-drug conjugate therapeutics for patients with cancer, on its definitive agreement to be acquired for $1.8 billion in an all-cash transaction by Genmab (NASDAQ: GMAB), a dual-listed, international biotechnology company that creates and develops differentiated antibody therapeutics to fight against cancer and other serious diseases.
Related contacts
Related Practices & Industries
Adaptive Phage Therapeutics Enters Into Definitive Merger Agreement With BiomX
March 6, 2024
Cooley advised Adaptive Phage Therapeutics, a US-based, privately held, clinical-stage biotechnology company pioneering the development of phage-based therapies to combat bacterial infections, on its definitive merger agreement with BiomX, a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria.
Related contacts
Rubicon Technology Partners Announces Strategic Majority Investment in Vimly Benefit Solutions
February 13, 2024
Cooley advised Rubicon Technology Partners – a Boulder, Colorado-based private equity firm focused exclusively on investing in and growing software companies – on its majority strategic investment in Vimly Benefit Solutions, a leader in the benefits administration space.
Related contacts
Related Practices & Industries
RayzeBio Signs Approximately $4.1 Billion Acquisition Agreement With Bristol Myers Squibb
December 26, 2023
Cooley advised RayzeBio, a clinical-stage radiopharmaceutical therapeutics (RPT) company with an innovation-leading position in actinium-based RPTs and a pipeline of potentially first-in-class and best-in-class drug development programs, on its definitive agreement to be acquired by Bristol Myers Squibb.
Related contacts
Related Practices & Industries
Carmot Therapeutics Enters Definitive Merger Agreement With Roche
December 3, 2023
Cooley advised Carmot Therapeutics, a clinical-stage biotechnology company dedicated to developing life-changing therapeutics for people living with metabolic diseases including obesity and diabetes, on its definitive merger agreement in which Roche will acquire Carmot.
Related contacts
Related Practices & Industries
Admissions & credentials
California